Tempus AI slides 5.5% as post-guidance volatility and shelf overhang weigh
Tempus AI shares fell about 5.5% on April 2, 2026, extending a recent pullback after a strong run earlier in the year. The move appears driven by continued post-results digestion and positioning after the company’s 2026 outlook raise and ESOP-linked shelf filing in early March.
1) What’s moving the stock today
Tempus AI (TEM) traded lower on April 2, 2026, in what looks like an extension of the stock’s recent volatility rather than a single fresh headline. The selling pressure follows a period in which investors have been weighing the implications of Tempus lifting its 2026 outlook while also introducing a new potential supply overhang via an ESOP-related shelf registration filed in early March.
2) The catalyst backdrop investors are still pricing in
In early March, Tempus disclosed stronger full-year 2025 results, issued 2026 revenue guidance around $1.59 billion, and launched its HRD-RNA oncology algorithm. At the same time, it filed a roughly $343 million Class A common stock shelf registration tied to an ESOP offering—an action that can amplify near-term sensitivity to any incremental selling or perceived dilution risk as traders reassess positioning.
3) Why the move is showing up as a sharper down day
After a large multi-month advance and heavy attention from momentum-oriented investors, TEM has been prone to air pockets when there is no new positive catalyst. With the market still digesting the combination of faster growth guidance and the prospect of additional shares becoming available over time, intraday sellers have been able to push the stock down more quickly than on a typical session.